Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 118,886

Document Document Title
WO/2016/132233A1
The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage f...  
WO/2016/131947A1
The present invention relates and the combination of lacosamide and brivaracetam for the preparation of a fixed dose combination that is useful in the treatment of epilepsy, epileptogenesis, seizure disorders and convulsions.  
WO/2016/131640A1
The present invention provides a medium chain fatty acid (MCFA) for use in treating and/or preventing anxiety.  
WO/2016/132343A1
The present invention describes a process for the synthesis of 3-(2-cyanophenyl)-5-(2- pyridyl)-1-phenyl-1,2-dihydro-pyridin-2-one (Perampanel) represented by the structure of formula (1), and salts thereof, especially salts with pharmac...  
WO/2016/133788A1
Provided are methods and compositions for preventing, reducing, mitigating and treating pain, particularly neuropathic pain by the combined administration of an agent that increases EETs and an agent that reduces/inhibits endoplasmic ret...  
WO/2016/134049A1
Aspects of the invention relate generally to the treatment of schizophrenia in an individual and, more specifically, to the treatment of an individual with iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt the...  
WO/2016/134032A1
Provided are methods for treating or preventing brain edema in a subject by administering an inhibitor of SLC26A11 to the subject. Also included are methods for preventing cell death, cell swelling, or elevated internal concentration of ...  
WO/2016/134292A1
Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.  
WO/2016/133446A1
The compound N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl )-1,3,5-triazine- 2,4-diamineor a pharmaceutically acceptable salt of said compound. The compound is useful the treatment of a condition or disorder associated wit...  
WO/2016/134042A3
In certain embodiments compounds (e.g., triazolopyrimidine(s) and/or triazolopyridine(s)) are provided that are effective to lower p-tau and/or to prevent or reduce elevation of p-tau, particularly in response to stress (e.g., elevated c...  
WO/2016/134246A3
The present invention relates to the field of protein conformational diseases. More specifically, the present invention provides compositions and methods for treating protein conformational diseases including amyotrophic lateral sclerosi...  
WO/2016/134042A2
In certain embodiments compounds (e.g., triazolopyrimidine(s) and/or triazolopyridine(s)) are provided that are effective to lower p-tau and/or to prevent or reduce elevation of p-tau, particularly in response to stress (e.g., elevated c...  
WO/2016/128132A1
Novel 2-oxoesters are described. Also described are uses thereof, such as for inhibition of phospholipase A2 activity. Therapeutic uses thereof are also described, such as for the treatment of neural conditions and/or inflammatory condit...  
WO/2016/130589A3
Provided herein are RNAi molecules including a first strand containing a guide sequence and a second strand comprising a non-guide sequence where the non-guide sequence contains a bulge opposite the seed region of the guide sequences; e....  
WO/2016/127962A1
The invention relates to a novel, physically stable, solid form of suvorexant, chemically [(7R)- 4-(5-chloro- 1,3 -benzoxazol-2-yl)-7-methyl- 1,4-diazepan- 1 -yl] [5-methyl- 2-(2H-l,2;3-triazol-2-yl)phenyl]methanone with sulphuric acid, ...  
WO/2016/127831A1
The present invention provides an application of chlorogenic acid in preparing medicines for treating the Parkinson's disease.  
WO/2016/129627A1
The present invention provides a screening method for pain-relieving substances, said method characterized by the use of FLRT3 to select substances that inhibit the expression of FLRT3, or substances that inhibit transport of FLRT3 to th...  
WO/2016/130901A2
Compounds and methods for treating diseases or conditions affected by the activity or expression of genes/proteins related to human GH, GHR, STAT5, SOCS, IGF-1, insulin are provided. Monoclonal antibodies for treating diseases or conditi...  
WO/2016/130589A2
Provided herein are RNAi molecules including a first strand containing a guide sequence and a second strand comprising a non-guide sequence where the non-guide sequence contains a bulge opposite the seed region of the guide sequences; e....  
WO/2016/130920A2
Compounds having the formula (I), (II), (III) are provided. Compounds of the present disclosure are useful for the treatment of neurodegenerative diseases, such as Parkinson's Disease.  
WO/2016/128771A1
The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein: Z is OR16 or NR17R18; R16 is H or alkyl; R17 is H or alkyl; R18 is alkyl or cycloalkyl, each of which i...  
WO/2016/130796A1
Disclosed are compounds of Formula (I): (Formula (I)) and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These co...  
WO/2016/128990A1
The present invention relates to compounds of formula (I), including their stereoisomers and pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising su...  
WO/2016/127399A1
The present invention provides use of chlorogenic acid in preparing a drug for treating amyotrophic lateral sclerosis. The chlorogenic acid is beneficial to alleviating disease symptoms of amyotrophic lateral sclerosis (ALS), beneficial ...  
WO/2016/130460A2
Compounds, compositions, kits and methods for treating conditions related to Retinal degenerations, and related diseases, including retinitis pigmentosa and atrophic age-related macular degeneration, are disclosed.  
WO/2016/130460A3
Compounds, compositions, kits and methods for treating conditions related to Retinal degenerations, and related diseases, including retinitis pigmentosa and atrophic age-related macular degeneration, are disclosed.  
WO/2016/130901A3
Compounds and methods for treating diseases or conditions affected by the activity or expression of genes/proteins related to human GH, GHR, STAT5, SOCS, IGF-1, insulin are provided. Monoclonal antibodies for treating diseases or conditi...  
WO/2016/128772A1
The present invention relates to BKCa activators for use in the treatment of a muscular disorder, or for controlling spasticity or tremors, for example, spasticity in MS.  
WO/2016/129583A1
The invention provides a lactate dehydrogenase inhibitor that makes it possible to suppress refractory epilepsy in which conventional antiepileptic drugs are ineffective, and an antiepileptic drug containing said inhibitor. The lactate d...  
WO/2016/127221A1
The present invention relates to compositions, methods and kits for the treatment of pain. In particular, the compositions, methods and kits are for the treatment of pain associated with headache or migraine or period pain. In particular...  
WO/2016/130501A1
The present invention provides aza-heteroaryl derivatives of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A, W, R4, R5, and R6 are defined herein, that inhibit the activity of phosphoinositide 3-kinases-gamm...  
WO/2016/130460A9
Compounds, compositions, kits and methods for treating conditions related to Retinal degenerations, and related diseases, including retinitis pigmentosa and atrophic age-related macular degeneration, are disclosed.  
WO/2016/129140A1
An intraoral rapid disintegration tablet that comprises fine grains, said fine grains having, at the center, a drug substance-containing core containing butylscopolamine bromide and water-insoluble particles and being provided with an in...  
WO/2016/130790A1
Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Ring B, A1, A2, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for...  
WO/2016/130920A3
Compounds having the formula (I), (II), (III) are provided. Compounds of the present disclosure are useful for the treatment of neurodegenerative diseases, such as Parkinson's Disease.  
WO/2016/127832A1
The present invention provides an application of chlorogenic acid in preparing medicines for treating epilepsy. The chlorogenic acid helps to relieve an epileptic attack.  
WO/2016/124788A1
The invention relates to a system for the intranasal sequential administration of at least one active principle pertaining to the group of active principles having at least one respiratory depression RD side effect and at least one activ...  
WO/2016/127068A1
Methods of treating postherpetic neuralgia in a mammal with a pharmaceutical composition comprising a spiro-oxindole compound of the formula:(the formula should be inserted here), are disclosed. The methods provide excellent penetration ...  
WO/2016/124129A1
Disclosed are a series of diaza-benzofluoranthrene compounds. The present invention particularly relates to a compound represented by formula (I), pharmaceutically acceptable salts or tautomers thereof.  
WO/2016/126572A2
Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthas...  
WO/2016/124642A1
The invention relates to the field of medicine and nutrition, more specifically to the field of treatment and prevention of human disorders such as depression, rumination, aggression, migraine, autistic spectrum disorders (including auti...  
WO/2016/126995A1
The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disord...  
WO/2016/125187A4
The patent discloses novel quinoline derivatives of formula (I), (Formula should be inserted here) and process for preparing the same. The compounds of formula (I) can be further used for the synthesis of Inhibitors like Kinase Tyrosine ...  
WO/2016/126929A1
The disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and dis...  
WO/2016/125190A3
Crystalline forms of vortioxetine hydrobromide, designated as form-M1, form-M2, form-M3, and form-M4are disclosed herein.The present disclosure also provides apharmaceutical premix of crystalline form-M2 of vortioxetine hydrobromide and ...  
WO/2016/126169A1
´╗┐The invention is based on the use of acetyl-L-carnitine (ALC) as a means for increasing the effectiveness of antidepressive treatment and can be used in a clinic in antidepressive treatment with non-natural antidepressants, such as ag...  
WO/2016/125190A2
Crystalline forms of vortioxetine hydrobromide, designated as form-M1, form-M2, form-M3, and form-M4are disclosed herein.The present disclosure also provides apharmaceutical premix of crystalline form-M2 of vortioxetine hydrobromide and ...  
WO/2016/125187A1
The patent discloses novel quinoline derivatives of formula (I), (Formula should be inserted here) and process for preparing the same. The compounds of formula (I) can be further used for the synthesis of Inhibitors like Kinase Tyrosine ...  
WO/2016/125208A1
The object of the invention is to provide a functional unknown material in which a natural product is used as a raw material. One embodiment of the invention is a yeast fermentation product of the nest of birds belonging to the genus Col...  
WO/2016/124508A1
The invention relates to 9H-pyrrolo-dipyridine derivatives of formula I, processes for preparing them, pharmaceutical compositions containing them and their use as radiopharmaceuticals in particular as imaging agents for the detection of...  

Matches 301 - 350 out of 118,886